"Nutritional and chemopreventive anti-cancer agents up-regulate expression of p27Kip1, a cyclin-dependent kinase inhibitor, in mouse JB6 epidermal and human MCF7, MDA-MB-321 and AU565 breast cancer cells"

Cancer Cell International

Volumn 6, Issue , 2006, Pages

  Eto, Isao ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 HYDROXYTAMOXIFEN; ANTINEOPLASTIC AGENT; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; DACTINOMYCIN; DAIDZEIN; GENISTEIN; GENISTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INTERACTING ENZYME; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL DEPENDENT KINASE; PHOSPHOTRANSFERASE; PROTEIN KINASE B; PROTEIN P27; PROTEIN TYROSINE KINASE; TAMOXIFEN; TRANSCRIPTION FACTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

5' UNTRANSLATED REGION; AMINO ACID DEFICIENCY; ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BREAST CANCER; CALORIC RESTRICTION; CANCER CELL CULTURE; CANCER PREVENTION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG BINDING SITE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; EPIDERMIS CELL; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; METABOLIC ACTIVATION; MOUSE; NONHUMAN; NUTRITIONAL SUPPORT; PRECANCER; PROTEIN EXPRESSION; RNA METHYLATION; RNA TRANSLATION; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS; UPREGULATION;

EID: 33748655440     PISSN: 14752867     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-6-20     Document Type: Article

References (43)

1. Kip1. Nature Cell Biol 2004, 6:1153-1155.
2. ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 1995, 270:23589-23597.
3. Henglein B, Chenivesse X, Wang J, Eick D, Brechot C: Structure and cell cycle-regulated transcription of the human cyclin A gene. Proc Natl Acad Sci USA 1994, 91:5490-5494.
4. Kip1 gene promoter. FEBS Lett 1997, 411:1-6.
5. Kullmann M, Gopfert U, Siewe B, Hengst L: ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5′UTR. Genes Dev 2002, 16:3087-3099.
6. Gopfert U, Kullmann M, Hengst L: Cell cycle-dependent translation of p27 involves a responsive element in its 5′-UTR that overlaps with a uORF. Hum Mol Genet 2003, 12:1767-1779.
7. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzier KW, Vogelstein B: WAFI, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825.
8. Hsu TC, Nair R, Tulsian P, Camalier CE, Hegamyer GA, Young MR, Colburn NH: Transformation nonresponsive cells owe their resistance to lack of p65/nuclear factor-κB activation. Cancer Res 2001, 61:4160-4168.
9. Liu Z, Kokunai T, Tamaki N: Tamoxifen interacts with NEU/c-ERIBB-2 receptor and inhibits growth of human malignant glioma cell lines. Kobe J Med Sci 2001, 47:131-140.
10. Nedeljkovic A, Radulovic S, Bjelogrlic S: Pleiotropic effect of genistein makes it a promising cancer protective compound. Arch Oncol 2001, 9:171-174.
11. Sah JF, Balasubramanian S, Eckert RL, Rorke EA: Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERKI/2 and Akt kinases. J Biol Chem 2004, 279:12755-12762.
12. Masuda M, Suzui M, Lim JT, Weinstein IB: Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin Cancer Res 2003, 9:3486-3491.
13. Inoki K, Corradetti MN, Guan KL: Dysregulation of the TSC-mTOR pathway in human disease. Nature Genetics 2005, 37:19-24.
14. Ohanna M, Sobering AK, Lapointe T, Lorenzo L, Praud C, Petroulakis E, Sonenberg N, Kelly PA, Sotiropoulos A, Pende M: Atrophy of S6K1-/ -skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nature Cell Biol 2005, 7:286-294.
15. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108:1167-1174.
16. Agrawal D, Hauser P, McPherson F, Dong F, Garcia A, Pledger WJ: Repression of p27Kip1 synthesis by platelet-derived growth factor in BALBc/3T3 cells. Mol Cell Biol 1996, 16:4327-4336.
17. Hengst L, Reed SI: Translational control of p27Kip1 accumulation during the cell cycle. Science 1996, 271:1861-1864.
18. Millard SS, Yan JS, Nguyen H, Pagano M, Kiyokawa H, Koff A: Enhanced ribosomal association of p27(Kip1) mRNA in a mechanism contributing to accumulation during growth arrest. J Biol Chem 1997, 272:7093-7098.
19. Miskimins WK, Wang G, Hawkinson M, Miskimins R: Control of cyclin-dependent kinase inhibitor p27 expression by cap-independent translation. Mol Cell Biol 2001, 21: 4960-4967.
20. Millard SS, Vidal A, Markus M, Koff A: A U-rich element in the 5′ untranslated region is necessary for the translation of p27 mRNA. Mol Cell Biol 2000, 20:5947-5959.
21. Hardie DG: AMP-activated protein kinase: the guardian of cardiac energy status. J Clin Invest 2004, 114:465-468.
22. Hardie DG: The AMP-activated protein kinase pathway - new players upstream and downstream. J Cell Sci 2004, 117.5479-5487.
23. Nicholson KM, Anderson NG: The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal 2002, 14:381-395.
24. Hinault C, Mothe-Satney I, Gautier N, Lawrence JC Jr, Van Obberghen E: Amino acids and leucine allow insulin activation of the PKB/mTOR pathway in normal adipocytes treated with wortmannin and in adipocytes from db/ db mice. FASEB J 2004, 18:1894-1896.
25. Knauf U, Tschopp C, Gram H: Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol Cell Biol 2001, 21:5500-5511.
26. Shatkin AJ, Manley JL: The ends of the affair: capping and polyadenylation. Nat Struct Biol 2000, 7:838-842.
27. Shuman S, Lima CD: The polynucleotide ligase and RNA capping enzyme superfamily of covalent nucleotidyltransferases. Curr Opin Struct Biol 2004, 14:757-764.
28. Gu M, Lima CD: Processing the message: structural insights into capping and decapping mRNA. Curr Opin Struct Biol 2005, 15:99-106.
29. Holstein SA, Wohlford-Lenane CL, Hohl RJ: Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rapla, RhoA, and RhoB. J Biol Chem 2002, 277:10678-10682.
30. Jiang H, Coleman J, Miskimins R, Miskimins WK: Expression of constitutively active 4EBP-I enhances p27Kip1 expression and inhibits proliferation of MCF7 breast cancer cells. Cancer Cell Int 2003, 3:2.
31. King TD, Song L, Jope RS: AMP-activated protein kinase (AMPK) activating agents cause dephosphorylation of Akt and glycogen synthase kinase-3. Biochem Pharmacol 2006, 71:1637-1647.
32. Hahn-Windgassen A. Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N: Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 2005, 280:32081-32089.
33. Suzuki A, Kusakai G, Kishimoto A, Shimojo Y, Ogura T, Lavin MF, Esumi H: IGF-I phosphorylates AMPKα subunit in ATM-dependent and LKBI-independent manner. Biochem Biophys Res Commun 2004, 324:986-992.
34. Dokladda K, Green KA, Pan DA, Hardie DG: PD98059 and U0126 activate AMP-activated protein kinase by increasing the cellular AMP:ATP ratio and not via inhibition of the MAP kinase pathway. FEBS Lett 2005, 579:236-240.
35. Rattan R, Giri S, Singh AK, Singh I: 5-Aminoimidazole-4-carboxamide-I-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 2005, 280:39582-39593.
36. Longnus SL, Segalen C, Giudicelli J, Salan MP, Farese RV, Van Obberghen E: Insulin signaling downstream of protein kinase B is potentiated by 5′AMP-activated protein kinase in rat hearts in vivo. Diabetologia 2005, 48:2591-2601.
37. Han S, Khuri FR, Roman J: Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKBI/AMP-activated protein kinase signal pathways. Cancer Res 2006, 66:315-323.
38. Davis BJ, Xie Z, Viollet B, Zou MH: Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 2006, 55:496-505.
39. Hattori Y, Suzuki K, Hattori S, Kasai K: Metformin inhibits cytokine-induced factor κB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006, 47:1183-1188.
40. Soltys CL, Kovacic S, Dyck JR: Activation of cardiac AMP-activated protein kinase by LKBI expression or chemical hypoxia is blunted by increased Akt activity. Am J Physiol Heart Circ Physiol 2006, 290:H2472-H2479.
41. Dagon Y, Avraham Y, Berry EM: AMPK activation regulates apoptosis, adipogenesis, and lipolysis by eIF2α in adipocytes. Biochem Biophys Res Commun 2006, 340:43-47.
42. Jun T, Gjoerup O, Roberts TM: Tangled web: evidence of crosstalk between c-Raf-I and Akt. Sci STKE 1999, 1999:PEI.
43. Sprenkle AB, Davies SP, Carling D, Hardie DG, Sturgill TW: Identification of Raf-I Ser621 kinase activity from NIH 3T3 cells as AMP-activated protein kinase. FEBS Lett 1997, 403:254-258.